Success Metrics

Clinical Success Rate

88.9%

Based on 8 completed trials

Completion Rate

89%(8/9)

Active Trials

0(0%)

Results Posted

25%(2 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_1

78%

Ph phase_2

22%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

7(77.8%)

Phase 2Efficacy & side effects

2(22.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Terminated(1)

Detailed Status

Completed8

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.9%

Most Advanced

Phase 2

Trials by Phase

Phase 17 (77.8%)

Phase 22 (22.2%)

Trials by Status

terminated111%

completed889%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_2

Clinical Trials (9)

Showing 9 of 9 trials

NCT04433585Phase 2

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

Completed

NCT04119557Phase 1

A Study of LY3471851 in Participants With Psoriasis

Completed

NCT04081350Phase 1

A Study of LY3471851 in Participants With Eczema

Completed

NCT04133116Phase 1

A Study of LY3471851 in Healthy Participants

Completed

NCT05565729Phase 1

A Phase I Study of LY3471851 in Healthy Participants

Completed

NCT03556007Phase 1

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

Completed

NCT04998487Phase 1

A Single-Dose Study of LY3471851 in Healthy Participants

Completed

NCT04380324Phase 1

A Study of NKTR-358 (LY3471851) in Healthy Participants

Completed

NCT04677179Phase 2

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Terminated

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9